Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2016 · 10-Q
Revenue$3.61M$3.61M−90.1% vs Q2 2015 Net Income-$2.84M-$2.84MN/M vs Q2 2015 EPS Diluted-$1.29-$1.29N/M vs Q2 2015 Gross Profit$1,770,000+340.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,301,000N/M Margins · derivedGross margin49.0%+47.9 pt vs Q2 2015
Operating margin-80.1%−58.9 pt vs Q2 2015
Net margin-78.7%−58.1 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 15, 2016 · 46 d after period end